Co-Authors
This is a "connection" page, showing publications co-authored by KAREN H LU and THOMAS W BURKE.
Connection Strength
0.845
-
Early cervical cancer. Curr Treat Options Oncol. 2000 Jun; 1(2):147-55.
Score: 0.183
-
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
Score: 0.110
-
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res. 2008 May 01; 14(9):2543-50.
Score: 0.079
-
Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6.
Score: 0.064
-
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar; 105(3):569-74.
Score: 0.064
-
Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005 Mar; 105(3):575-80.
Score: 0.064
-
Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004 Oct; 95(1):32-6.
Score: 0.062
-
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 01; 22(15):3126-32.
Score: 0.061
-
Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):748-52.
Score: 0.060
-
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
Score: 0.058
-
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
Score: 0.023
-
Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):77-83.
Score: 0.016